FDA Grants Accelerated Approval to Lynozyfic
A bispecific T-cell engager that targets BCMA on myeloma cells and CD3 on T-cellsFor hard-to-treat multiple myeloma
On July 2, 2025, the FDA granted accelerated approval to linvoseltamab-gcpt (brand name: Lynozyfic) for adults with relapsed or refractory multiple myeloma who have received at least four prior therapies, including:
- A proteasome inhibitor (PI)
- An immunomodulatory agent (IMiD)
- An anti-CD38 monoclonal antibody
How It Works
Lynozyfic is a bispecific T-cell engager that targets BCMA on myeloma cells and CD3 on T-cells, directing the immune system to attack cancer cells.
Clinical Trial Highlights (LINKER-MM1)
- Patients in the study had received a median of 4 prior lines of therapy
- 70% overall response rate (ORR)
- Estimated duration of response (DOR):
- 89% at 9 months
- 72% at 12 months
Safety & Risk
Lynozyfic carries a Boxed Warning for:
- Cytokine Release Syndrome (CRS) — occurred in 46% of patients
- Neurologic toxicity (including ICANS) — occurred in 54% of patients
- Grade 3 or higher neurologic events in 8%
- Grade 3 CRS in <1%
Due to serious risks, the drug is available only through the restricted Lynozyfic Risk Evaluation and Mitigation Strategy (REMS) program. Important components of the REM program include the education of patients, in-hospital dosing, close monitoring and measurement of conditions and results, and a patient wallet card that describes the indicators of CRS and neurologic issues.
Full prescribing information for Lynozyfic will be posted on Drugs@FDA.
Additional warnings
- Infections
- Neutropenia
- Liver toxicity
- Embryo-fetal toxicity
Dosing Overview
- IV administration with step-up dosing: 5 mg → 25 mg → 200 mg
- Then 200 mg weekly ×10, then every 2 weeks
- If stable with partial response or better after week 24: dosing reduced to every 4 weeks
Expedited Designations
- Priority Review
- Fast Track
- Orphan Drug designation
Lynozyfic offers a new immunotherapy option for patients with highly resistant multiple myeloma, though it requires close monitoring due to serious side effects.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
Why These Salmonella Outbreaks Keep Happening
Why These Salmonella Outbreaks Keep Happening: “Illness First, Controls Later” An MDP Consumer and Industry Brief When people hear “FDA is investigating,” they often assume the system detected a safety problem early and intervened. In many dietary supplement...
Four Moringa-Linked Salmonella Events in Four Months
Four Moringa-Linked Salmonella Events in Four Months: The Timeline That Should Not Exist An MDP Consumer and Industry Brief A single recall can be dismissed as a one-time failure. Two recalls in the same ingredient category raise questions. But when moringa-based...
Moringa and the “Invisible Outbreak” Problem
Moringa and the “Invisible Outbreak” Problem in Supplements An MDP Consumer and Industry Brief Most Americans assume dietary supplements are monitored for safety in the same way as conventional foods or pharmaceutical products. But many supplement contamination events...